Ya Gao

发表

Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.

Andrew P. Stubbs, R. Vernhout, M. J. van den Bent, 2016, Cancer research.

Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas

P. French, W. Vallentgoed, Ya Gao, 2018, Cancers.

Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas.

M. J. van den Bent, M. Taphoorn, T. Gorlia, 2015, Neuro-oncology.

PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients

M. J. van den Bent, M. Smid, P. French, 2015, Acta Neuropathologica Communications.

Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors

J. Aerts, P. French, P. S. Sillevis Smitt, 2020, EBioMedicine.

Effective Tyrosine Kinase Inhibitors result in the intracellular accumulation of EGFR and allows response prediction in patients

J. Aerts, P. French, M. V. van Royen, 2019 .

Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation.

Jeroen A. A. Demmers, J. Aerts, Y. Atlasi, 2014, European journal of cancer.

IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis

M. Lamfers, P. French, P. S. Sillevis Smitt, 2018, PloS one.

Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.

M. Hassel, K. Hoang-Xuan, R. Stupp, 2018, European journal of cancer.